Literature DB >> 28017733

Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.

Holly K Miller1, Thomas M Braun2, Terri Stillwell3, Andrew C Harris4, Sung Choi4, James Connelly4, Daniel Couriel4, Steven Goldstein4, Carrie L Kitko4, John Magenau4, Attaphol Pawarode4, Pavan Reddy4, Mary Riwes4, Gregory A Yanik4, John E Levine5.   

Abstract

The occurrence of infections after allogeneic hematopoietic stem cell transplantation (HCT) is nearly universal. However, the relationship between infections and graft-versus-host disease (GVHD) is complex and attribution of infectious-related mortality is highly inconsistent, making comparison of infectious complication rates across allogeneic HCT clinical studies difficult. We categorized infectious complications from diagnosis or 1 year before HCT (whichever occurred later) through 2 years after HCT according to timing, frequency, causative organism, severity, and contribution to mortality for 431 consecutive patients who underwent allogeneic HCT from 2008 to 2011. We then assessed the contribution of risk factors, such as the frequency of pre-HCT infections and post-HCT GVHD, on post-HCT infection frequency and severity. We found that each pre-HCT bacterial infection/year leads to an additional 2.15 post-HCT bacterial infection/year (P = .004). Pre-HCT viral and fungal infections were not predictors for post-HCT infections. Acute GVHD (aGVHD) significantly increased the risk of developing life-threatening (hazard ratio [HR], 1.97; 95% confidence interval [CI], 1.33 to 2.90) and fatal (HR, 2.8; 95% CI, 1.10 to 7.08) infections. Furthermore, patients who develop aGVHD experienced ~60% more infections than patients who never develop aGVHD. Quantification of infection frequency and severity for patients with and without GVHD may facilitate comparison of infectious outcomes across allogeneic HCT trials.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute graft-versus-host-disease; Fatal infection; Infection

Mesh:

Year:  2016        PMID: 28017733      PMCID: PMC5551893          DOI: 10.1016/j.bbmt.2016.12.630

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  32 in total

1.  Diagnostic strategies for invasive fungal infections in patients with hematologic malignancies and hematopoietic stem cell transplant recipients.

Authors:  Maxim Norkin; John R Wingard
Journal:  J Natl Compr Canc Netw       Date:  2013-08       Impact factor: 11.908

2.  Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.

Authors:  Sophie Servais; Etienne Lengline; Raphaël Porcher; Maryvonnick Carmagnat; Régis Peffault de Latour; Marie Robin; Flore Sicre de Fontebrune; Emmanuel Clave; Guitta Maki; Clémence Granier; Alienor Xhaard; Nathalie Dhedin; Jean-Michel Molina; Antoine Toubert; Hélène Moins-Teisserenc; Gérard Socie
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-07       Impact factor: 5.742

Review 3.  Antimicrobial prophylaxis regimens following transplantation.

Authors:  Aruna K Subramanian
Journal:  Curr Opin Infect Dis       Date:  2011-08       Impact factor: 4.915

4.  Infections diagnosed in the first year after pediatric stem cell transplantation.

Authors:  Daniel Kelly Benjamin; William C Miller; Sherry Bayliff; Lisa Martel; Kenneth A Alexander; Paul Langlie Martin
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

Review 5.  Extracorporeal photopheresis in acute and chronic graft-versus-host disease.

Authors:  Hildegard T Greinix; Nina Worel; Ulrike Just; Robert Knobler
Journal:  Transfus Apher Sci       Date:  2014-04-13       Impact factor: 1.764

Review 6.  Update of hematopoietic cell transplantation for sickle cell disease.

Authors:  Mark C Walters
Journal:  Curr Opin Hematol       Date:  2015-05       Impact factor: 3.284

7.  Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Amin M Alousi; Daniel J Weisdorf; Brent R Logan; Javier Bolaños-Meade; Shelly Carter; Nancy Difronzo; Marcelo Pasquini; Steven C Goldstein; Vincent T Ho; Brandon Hayes-Lattin; John R Wingard; Mary M Horowitz; John E Levine
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

8.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

9.  Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance.

Authors:  Allison M Bock; Qing Cao; Patricia Ferrieri; Jo-Anne H Young; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-29       Impact factor: 5.742

Review 10.  The challenge of emerging and re-emerging infectious diseases.

Authors:  David M Morens; Gregory K Folkers; Anthony S Fauci
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

View more
  15 in total

1.  Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation.

Authors:  Ramona Gilles; Marco Herling; Udo Holtick; Eva Heger; Sabine Awerkiew; Irina Fish; Konstantin Höller; Saleta Sierra; Elena Knops; Rolf Kaiser; Christof Scheid; Veronica Di Cristanziano
Journal:  Med Microbiol Immunol       Date:  2017-07-12       Impact factor: 3.402

2.  Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.

Authors:  Andrew Kent; Sumithira Vasu; Derek Schatz; Natalie Monson; Steven Devine; Clayton Smith; Jonathan A Gutman; Daniel A Pollyea
Journal:  Blood Adv       Date:  2020-07-14

3.  Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation.

Authors:  Stéphane Buhler; Florence Bettens; Carole Dantin; Sylvie Ferrari-Lacraz; Marc Ansari; Anne-Claire Mamez; Stavroula Masouridi-Levrat; Yves Chalandon; Jean Villard
Journal:  Leukemia       Date:  2019-11-26       Impact factor: 11.528

Review 4.  Graft-Versus-Host Disease After Liver Transplantation.

Authors:  Ashley Wood; Bijan Eghtesad; Christina C Lindenmeyer
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-26

Review 5.  Beyond Cytomegalovirus and Epstein-Barr Virus: a Review of Viruses Composing the Blood Virome of Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients.

Authors:  Marie-Céline Zanella; Samuel Cordey; Laurent Kaiser
Journal:  Clin Microbiol Rev       Date:  2020-08-26       Impact factor: 26.132

6.  MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

Authors:  Hannah Major-Monfried; Anne S Renteria; Attaphol Pawarode; Pavan Reddy; Francis Ayuk; Ernst Holler; Yvonne A Efebera; William J Hogan; Matthias Wölfl; Muna Qayed; Elizabeth O Hexner; Kitsada Wudhikarn; Rainer Ordemann; Rachel Young; Jay Shah; Matthew J Hartwell; Mohammed S Chaudhry; Mina Aziz; Aaron Etra; Gregory A Yanik; Nicolaus Kröger; Daniela Weber; Yi-Bin Chen; Ryotaro Nakamura; Wolf Rösler; Carrie L Kitko; Andrew C Harris; Michael Pulsipher; Ran Reshef; Steven Kowalyk; George Morales; Ivan Torres; Umut Özbek; James L M Ferrara; John E Levine
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

7.  Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.

Authors:  Ricardo Melendez-Munoz; Rachel Marchalik; Theresa Jerussi; Dimana Dimitrova; Veronique Nussenblatt; Andrea Beri; Khalid Rai; Jennifer S Wilder; A John Barrett; Minoo Battiwalla; Richard W Childs; Courtney D Fitzhugh; Daniel H Fowler; Terry J Fry; Ronald E Gress; Matthew M Hsieh; Sawa Ito; Elizabeth M Kang; Steven Z Pavletic; Nirali N Shah; John F Tisdale; Juan Gea-Banacloche; Christopher G Kanakry; Jennifer A Kanakry
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-18       Impact factor: 5.742

8.  Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.

Authors:  Makda Getachew Zewde; George Morales; Isha Gandhi; Umut Özbek; Paibel Aguayo-Hiraldo; Francis Ayuk; Janna Baez; Chantiya Chanswangphuwana; Hannah Choe; Zachariah DeFilipp; Aaron Etra; Stephan Grupp; Elizabeth O Hexner; William Hogan; Nora Rebeka Javorniczky; Stelios Kasikis; Carrie L Kitko; Steven Kowalyk; Elisabeth Meedt; Pietro Merli; Ryotaro Nakamura; Muna Qayed; Ran Reshef; Wolf Rösler; Tal Schechter; Daniela Weber; Matthias Wölfl; Gregory Yanik; Rachel Young; John E Levine; James L M Ferrara; Yi-Bin Chen
Journal:  Transplant Cell Ther       Date:  2021-08-30

9.  Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction.

Authors:  Peter van Balen; Boris van der Zouwen; Alwine B Kruisselbrink; Matthijs Eefting; Karoly Szuhai; Ekaterina S Jordanova; J H F Falkenburg; Inge Jedema
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

Review 10.  Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review.

Authors:  Freya Wenzel; Anne Pralong; Udo Holtick; Christoph Scheid; Marco Herling; Steffen T Simon
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.